- OS Therapies' lead clinical program, **OST-HER2**, for Osteosarcoma, has demonstrated **positive Phase 2b data**, reporting a **12-month Event Free Survival of 35%** and **2-year Overall Survival of 75%** in the treated group.  **[1795091_0001213900-25-100019_ea026125701ex99-1_osthera.htm:3]**  The company aims for **FDA Accelerated Approval by Q2/Q3 2026**.  **[1795091_0001213900-25-100019_ea026125701ex99-1_osthera.htm:1]** 
- Key regulatory milestones for OST-HER2 in human osteosarcoma include **UK MHRA MAA Filing in December 2025**, **US FDA BLA Filing in January 2026**, and **EMA MAA Filing in Q1/2026**.  **[1795091_0001213900-25-100019_ea026125701ex99-1_osthera.htm:3]** 
- As of October 2025, the company holds approximately **$4 million in cash** with a **monthly cash burn of $300K**.  **[1795091_0001213900-25-100019_ea026125701ex99-1_osthera.htm:1]**  The estimated market opportunity for OST-HER2 in human osteosarcoma is **$500 million+**, with an anticipated **$160 million** from the sale of a Priority Review Voucher upon FDA Accelerated Approval.  **[1795091_0001213900-25-100019_ea026125701ex99-1_osthera.htm:1]** 
- The 2025 annual meeting of stockholders, initially held on October 14, 2025, was **adjourned and will reconvene on October 21, 2025**, to allow for additional proxy solicitation.  **[1795091_0001213900-25-100019_ea0261257-8k_ostherapies.htm:2]**

OS Therapies Inc. Provides Update on OST-HER2 Clinical Program and Annual Meeting Adjournment

- OS Therapies Inc. completed a warrant inducement and exchange offer on **September 2, 2025**, generating approximately **$3.7 million** in gross proceeds.  **[1795091_0001213900-25-083396_ea025556801ex99-1_ostherap.htm:0]** **[1795091_0001213900-25-083396_ea0255568-8k_ostherap.htm:1]** 
- The proceeds will primarily fund the acceleration of **OST-HER2** commercial launch preparations in the United States, extending the company's funding into **2027**.  **[1795091_0001213900-25-083396_ea025556801ex99-1_ostherap.htm:0]** **[1795091_0001213900-25-083396_ea0255568-8k_ostherap.htm:1]** 
- The transaction involved issuing new warrants with a **$3.00 per share** exercise price and a forced exercise provision at **$9.00**, which could yield over **$20 million** in additional funding if triggered.  **[1795091_0001213900-25-083396_ea025556801ex99-1_ostherap.htm:0]** **[1795091_0001213900-25-083396_ea0255568-8k_ostherap.htm:2]** 
- This strategic move is expected to bring forward the potential commercialization of **OST-HER2** in the US into **early 2026**, pending FDA regulatory approval.  **[1795091_0001213900-25-083396_ea025556801ex99-1_ostherap.htm:0]**

OS Therapies Completes Warrant Inducement and Exchange Offer

- OS Therapies Inc. **terminated its Equity Purchase Agreement** (ELOC) with Square Gate Capital Master Fund, LLC — Series 3, effective **August 26, 2025**.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]** 
- The ELOC previously provided the company with the right to sell up to **$15.0 million** of its common stock.  **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]** 
- The termination was prompted by a recent warrant exercise inducement and exchange offering that provided OS Therapies with **$4.2 million** in gross proceeds.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** 
- These proceeds are expected to fund the company's operations into **mid-year 2026**, extending through the priority review voucher sunset date of **September 30, 2026**.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** 
- No outstanding borrowings, advance notices, shares to be issued, or termination fees were due by either party in connection with the termination.  **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]**

OS Therapies (OSTX)